Trial Profile
A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2020
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary)
- Indications Cardiomyopathies
- Focus Proof of concept; Therapeutic Use
- Acronyms preTopic
- 04 Jul 2020 Status changed from recruiting to discontinued.
- 15 Jan 2018 New trial record